PresentationHello, and welcome to Wave Life Sciences Positive Interim Clinical Data from INLIGHT Trial of WVE-007 and Obesity call. [Operator Instructions]. Also, as a reminder, this conference is being recorded today. I will now turn the call over to Kate Rausch, Vice President, Investor Relations and Corporate Affairs.Kate RauschHead of Investor Relations Thank you, operator. This morning, we issued a press release announcing positive interim clinical data from our ongoing Phase I INLIGHT trial of WVE-007 ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday.The Dow traded down 0.46% to 47,733.58 while the NASDAQ fell 0.32% to 23,501.92. The S&P 500 also fell, dropping, 0.46% to 6,838.69.Check This Out: Top 3 Materials Stocks That Are Preparing To Pump In Q4Leading and Lagging SectorsInformation technology shares jumped by 0.6% on Monday.In trading on Monday, communication services stocks fell by 2.1%.Top HeadlineThe one-year-ahead median inflation e ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday.The Dow traded down 0.46% to 47,733.58 while the NASDAQ fell 0.32% to 23,501.92. The S&P 500 also fell, dropping, 0.46% to 6,838.69.Check This Out: Top 3 Materials Stocks That Are Preparing To Pump In Q4Leading and Lagging SectorsInformation technology shares jumped by 0.6% on Monday.In trading on Monday, communication services stocks fell by 2.1%.Top HeadlineThe one-year-ahead median inflation e ...

Group 1 - U.S. stocks experienced a decline, with the Dow Jones falling over 200 points on Monday [1] - Paramount Skydance Corporation launched an all-cash tender offer to acquire Warner Bros. Discovery, Inc. for $30 per share, valuing the company at $108.4 billion [1] - Paramount aims to create a scaled Hollywood leader by merging with Warner Bros. [1] Group 2 - Paramount Skydance shares increased by 9.8% to $14.68 on Monday [2] - Other notable stocks that gained include Wave Life Sciences Ltd., which rose 129.1% to $17.16 after positive interim Phase 1 data for its obesity drug [4] - Structure Therapeutics Inc. saw a gain of 100.5% to $69.30 following the announcement of topline data from its clinical program for obesity treatment [4] Group 3 - Fulcrum Therapeutics, Inc. shares rose 62.3% to $14.44 after reporting initial results from its Phase 1b trial for sickle cell disease [4] - Kymera Therapeutics, Inc. gained 51.2% to $100.75 after reporting successful trial results for its KT-621 drug [4] - Confluent, Inc. shares increased by 29.2% to $29.89 after IBM agreed to acquire the company for $31 per share [4]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

研究显示单次240毫克剂量的WVE-007可使内脏脂肪减少9.4%，全身脂肪减少4.5%，瘦体重增加3.2%。 Wave Life Sciences还称，中期数据进一步表明，WVE-007总体上安全且耐受性良好，仅出现轻微的治 疗相关不良事件。预计2026年第一季度将发布进一步的临床数据更新，其中包括240毫克单剂量组的六 个月随访数据。 来源：智通财经网 周一，Wave Life Sciences(WVE.US)开盘飙升近80%，创年内新高，报13.42美元。消息面上，该公司表 示，其用于治疗肥胖症的WVE-007一期试验的中期数据显示，身体成分有所改善，在最低治疗剂量 下，体重减轻效果与GLP-1类似，但没有肌肉损失。 ...

研究显示单次240毫克剂量的WVE-007可使内脏脂肪减少9.4%，全身脂肪减少4.5%，瘦体重增加3.2%。 Wave Life Sciences还称，中期数据进一步表明，WVE-007总体上安全且耐受性良好，仅出现轻微的治 疗相关不良事件。预计2026年第一季度将发布进一步的临床数据更新，其中包括240毫克单剂量组的六 个月随访数据。 智通财经APP获悉，周一，Wave Life Sciences(WVE.US)开盘飙升近80%，创年内新高，报13.42美元。 消息面上，该公司表示，其用于治疗肥胖症的WVE-007一期试验的中期数据显示，身体成分有所改 善，在最低治疗剂量下，体重减轻效果与GLP-1类似，但没有肌肉损失。 ...

周一，Wave Life Sciences(WVE.US)开盘飙升近80%，创年内新高，报13.42美元。消息面上，该公司表 示，其用于治疗肥胖症的WVE-007一期试验的中期数据显示，身体成分有所改善，在最低治疗剂量 下，体重减轻效果与GLP-1类似，但没有肌肉损失。 研究显示单次240毫克剂量的WVE-007可使内脏脂肪减少9.4%，全身脂肪减少4.5%，瘦体重增加3.2%。 Wave Life Sciences还称，中期数据进一步表明，WVE-007总体上安全且耐受性良好，仅出现轻微的治 疗相关不良事件。预计2026年第一季度将发布进一步的临床数据更新，其中包括240毫克单剂量组的六 个月随访数据。 ...

Summary of Wave Life Sciences Conference Call Company Overview - **Company**: Wave Life Sciences (NasdaqGM: WVE) - **Focus**: Development of WVE-007, a treatment for obesity targeting Inhibin E Key Industry Insights - **Obesity Treatment Landscape**: - Individuals with obesity face higher risks of cardiovascular disease, type 2 diabetes, and certain cancers due to unhealthy body composition [6][8] - Current treatments like GLP-1 receptor agonists often lead to muscle mass loss, which is a significant concern [7][8] Core Findings from the IN-LIGHT Trial - **Clinical Data**: - Positive interim results from the Phase 1 IN-LIGHT trial of WVE-007 were announced, showing significant fat loss without muscle loss [2][4] - After three months, WVE-007 resulted in: - 4.5% reduction in total body fat - 9.4% reduction in visceral fat - 3.2% increase in lean mass [5][21] - These results were achieved without diet or exercise modifications [5][22] Mechanism of Action - **Target**: WVE-007 targets Inhibin E, which is linked to fat accumulation and metabolic disorders [10][11] - **Expected Outcomes**: - By silencing Inhibin E mRNA, WVE-007 aims to reduce abdominal fat while preserving muscle mass, potentially leading to improved cardiometabolic health [11][12][13] Safety and Tolerability - **Safety Profile**: - No serious treatment-emergent adverse events (TEAEs) or discontinuations reported across all dose cohorts [18][19] - All drug-related adverse events were mild, with no clinically meaningful changes in lipids, glucose, or liver function tests [18][19] Future Directions - **Next Steps**: - Continued evaluation of WVE-007 across different cohorts and longer follow-up periods [15][27] - Plans for Phase 2 trials in higher BMI populations with cardiometabolic comorbidities [26][27] Competitive Positioning - **Market Potential**: - WVE-007's once or twice yearly dosing could disrupt the obesity treatment market, especially compared to monthly GLP-1 treatments [32] - The focus on fat loss while preserving muscle mass aligns with FDA guidance on obesity therapies [32][35] Additional Considerations - **Biomarker Analysis**: - Ongoing collection of data on biomarkers related to inflammation and fibrosis, with expectations of improvements in lipid profiles and metabolic parameters in higher BMI populations [75][84] - **Patient Demographics**: - The trial included healthy individuals with mild obesity, which may limit the generalizability of results to more severe obesity cases [26][81] This summary encapsulates the key points discussed during the Wave Life Sciences conference call, highlighting the promising data from the IN-LIGHT trial and the potential impact of WVE-007 in the obesity treatment landscape.

INLIGHT临床试验是一项随机、安慰剂对照（试验组与安慰剂组比例为3:1）的1期研究，入组人群为超重或肥胖但无其他基础疾病的受试者， 其BMI范围在28至35千克/平方米之间， 糖化血红蛋白 （HbA1c）水平低于5.9%。该研究未对受试者施加任何饮食或运动干预。截至数据截止 日，INLIGHT临床试验已入组超100名受试者。本次公布的数据来自32名接受单次皮下注射240毫克WVE-007的受试者队列，其基线平均BMI约 为32千克/平方米，随访周期为三个月。所有公布结果均依据预设的统计分析方案得出。 在减肥药赛道，"减脂不减肌"一直是各大药企追求的"圣杯"。如今，一家名为 Wave Life Sciences 的生物技术公司似乎摸到了这个圣杯的边缘。 周一（12月8日），Wave 宣布其靶向 RNA 的肥胖疗法 WVE-007 在首个人体研究中取得了令人振奋的数据： 该药物不仅能显著减少患者的脂肪，还能 增加肌肉质量 ，受此消息影响， Wave Life Sciences 盘前暴涨超70%！ 核心提要： 美国马萨诸塞州剑桥市，2025年12月8日（环球通讯社）—— 波生命科学有限公司（纳斯达克股票代码：W ...